Analysis of transurethral water vapor thermal therapy for the treatment of benign prostatic hyperplasia.
- Author:
Ming-Yang PANG
1
;
Yong WEI
1
;
Jian-Zhong LIN
1
;
Jun WANG
1
;
Ming-Yu LIU
1
;
Fu-Yang LIU
1
;
Yi-Bo MA
1
;
Tong ZHAO
1
;
Qing-Yi ZHU
1
Author Information
1. Department of Urology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, China.
- Publication Type:Journal Article
- Keywords:
benign prostatic hyperplasia;
minimally invasive surgery;
water vapor thermal therapy;
sexual function
- MeSH:
Humans;
Male;
Prostatic Hyperplasia/therapy*;
Transurethral Resection of Prostate;
Steam;
Treatment Outcome;
Quality of Life;
Aged;
Middle Aged
- From:
National Journal of Andrology
2025;31(7):603-607
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy and safety of transurethral water vapor thermal therapy (WVTT) using the Rezūm system for benign prostatic hyperplasia (BPH) in the real world.
METHODS:A total of 181 patients with BPH were recruited from the Second Affiliated Hospital of Nanjing Medical University from August 2022 to December 2023, of whom 173 patients were treated with WVTT using the Rezūm system, while 8 patients were treated with WVTT combined with TURP. They were followed up at 1, 3, and 6 months postoperatively to assess changes in the IPSS, QoL, Qmax, IIEF-5, and the occurrence of any complications. Results： All 181 surgeries in this group were successfully completed. The operation time of the Rezūm system was (4.6 ± 1.4) minutes. The postoperative indwelling catheterization time was (8.0 ± 2.1) days. With a follow-up of at least 6 months, there was a significant decrease in PV, IPSS and QoL, and a remarkable increase had been found in Qmax as well (P<0.05). There was no significant difference in IIEF-5 before and after the operation (P>0.05). In this groups of patients, postoperative complications mainly included 95 cases (52.5%) of gross hematuria, 6 cases (3.3%) of retrograde ejaculation, 5 cases (2.8%) of urethral stricture, 4 cases (2.2%) of prostatitis, and 10 cases (5.5%) of urinary tract infection. Four cases (2.2%) underwent surgical retreatment for BPH after surgery.
CONCLUSION:In the real world, the use of Rezūm thermal steam ablation system for the treatment of BPH has satisfactory short-term effect, short surgical time, and significant improvement in IPSS, QoL, Qmax, which does not adversely affect sexual function.
